Integumen (AIM:SKIN) said its subsidiary, Labskin, has partnered with the University of Aberdeen to test anti-viral skin and dental products that could mitigate the transmission risk of coronavirus.
Scientists will use Labskin’s cloned human skin coated with the SARS-CoV-2 virus as part of the research which will take place in a Category 3 lab at the University of Aberdeen.
Work will be carried out assessing the transmissibility impact of the virus to and from human skin as well as the ability of the virus to remain infective while on the skin surface.
Shares in Integumen were trading 9.97% higher at 1.875p on Wednesday morning.
The aim of the study is to quantify the efficacy of mouthwash and dental care products as well as soap washing and hand sanitisers.
“It is important to find products that can help to mitigate the risk of infection, particularly, in professional settings,” said Gerard Brandon, Chief Executive of Integumen.
He said the group would study the effects of a variety of products and ingredients “without exposing human volunteers to dangerous and challenging clinical trial contamination risk.”
He added, “The more knowledge we have about SARS-CoV-2 - how it spreads, and more importantly, how to contain that spread - the better equipped to fight this virus we will be."
The group said results from the trial are expected in the next six weeks.
Follow News & Updates from Integumen here: